Bilimsel çalışmalar

Uzm. Dr. Safa Can Efil

36 yayın. Her yayının yanında bilginin kaynağı yazar.

Profile dön

  1. Resection and pathological response after neoadjuvant nivolumab plus chemotherapy for lung cancer in a Turkish Oncology Group (TOG) real-world study

    Research Square, 2026

    DOI 10.21203/rs.3.rs-11204389/v1 Açık erişimli tam metinKaynak: OpenAlex

  2. Nutritional Indexes and Their Variations as Predictors of Atezolizumab Plus Chemotherapy Efficacy in Extensive-Stage Small Cell Lung Cancer: A Turkish Oncology Group Study

    Journal of Immunotherapy, 2026

    DOI 10.1097/cji.0000000000000610 PMID 42267536 Kaynak: OpenAlex

  3. Pretreatment HALP Score and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors: A Turkish Oncology Group Kidney Cancer Consortium (TKCC) Study

    Cancers, 2026

    DOI 10.3390/cancers18132127 PMID 42449669 Açık erişimli tam metinKaynak: OpenAlex

  4. Prognostic impact of the Gustave Roussy Immune score in metastatic renal cell carcinoma treated with first-line immunotherapy-based combinations: results from the Turkish Oncology Group Kidney Cancer Consortium (TKCC)

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-16664-1 Açık erişimli tam metinKaynak: OpenAlex

  5. Comparison of 6 cycles with 4 cycles of chemotherapy and atezolizumab in the first-line treatment of ES-SCLC: a retrospective multicenter analysis

    The oncologist, 2026

    DOI 10.1093/oncolo/oyag092 PMID 41838398 Açık erişimli tam metinKaynak: ORCID

  6. Prognostic value of the glucose-to-lymphocyte ratio in surgically treated endometrial cancer: a retrospective cohort study

    Future Oncology, 2026

    DOI 10.1080/14796694.2026.2622299 PMID 41607196 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  7. Feasibility and Prognostic Value of an Ovarian NAR-like Score in Advanced Ovarian Cancer Treated with Neoadjuvant Chemotherapy and Interval Debulking Surgery

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15166266 PMID 42652669 Açık erişimli tam metinKaynak: ORCID

  8. Effects of Neoadjuvant Chemotherapy Treatment on Perioperative Outcomes Following Radical Cystectomy

    The New Journal of Urology, 2026

    DOI 10.33719/nju1831536 Açık erişimli tam metinKaynak: ORCID

  9. Association Between ABO Blood Group and Survival Outcomes in Advanced NSCLC Treated with Immune Checkpoint Inhibitors

    2026

    DOI 10.20944/preprints202606.1063.v1 Açık erişimli tam metinKaynak: ORCID

  10. Association Between ABO Blood Group and Survival Outcomes in Advanced NSCLC Treated with Immune Checkpoint Inhibitors

    Current Oncology, 2026

    DOI 10.3390/curroncol33100590 PMID 42930157 Açık erişimli tam metinKaynak: OpenAlex

  11. Real‐world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple‐negative breast cancer: A multicenter study by the Turkish Oncology Group

    International Journal of Cancer, 2025

    DOI 10.1002/ijc.70213 PMID 41147655 3 atıf (Europe PMC) Kaynak: OpenAlex

  12. Comparative efficacy of adjuvant FOLFOX vs. FLOT following neoadjuvant FLOT in patients with locally advanced gastric cancer

    Turkish journal of medical sciences, 2025

    DOI 10.55730/1300-0144.6002 PMID 40686717 Açık erişimli tam metinKaynak: Europe PMC

  13. Durvalumab-Based First-Line Chemoimmunotherapy in Advanced Biliary Tract Cancer: Real-World Outcomes and Prognostic Factors—A Turkish Oncology Group Study

    Cancers, 2025

    DOI 10.3390/cancers18010101 PMID 41514612 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  14. FOLFIRINOX: The Best Adjuvant Treatment for Ampullary Adenocarcinoma? A Multicenter Study by the Turkish Oncology Group (TOG)

    Cancers, 2025

    DOI 10.3390/cancers17172730 PMID 40940827 Açık erişimli tam metinKaynak: ORCID

  15. FOLFIRINOX: The best adjuvant treatment for ampullary adenocarcinoma?

    Journal of Clinical Oncology, 2025

    DOI 10.1200/jco.2025.43.16_suppl.e16261 Kaynak: ORCID

  16. Prognostic impact of hand-foot skin reaction in regorafenib-treated adult-type diffuse gliomas: A multicenter Turkish Oncology Group study

    Scientific Reports, 2025

    DOI 10.1038/s41598-025-19899-3 PMID 41102268 Açık erişimli tam metinKaynak: OpenAlex

  17. Comparison of the Efficacy of First-Line Pemetrexed-Platinum and Gemcitabine-Platinum Regimens in Malignant Peritoneal Mesothelioma

    Clinical Medicine Insights Oncology, 2025

    DOI 10.1177/11795549251385075 PMID 41133016 Açık erişimli tam metinKaynak: OpenAlex

  18. Synergistic prognostic effect of the renin‐angiotensin‐aldosterone system and immune‐checkpoint inhibition in advanced lung cancer: The SPERICIL study

    International Journal of Cancer, 2025

    DOI 10.1002/ijc.70169 PMID 41045097 3 atıf (OpenAlex) Kaynak: OpenAlex

  19. The effect of dose reduction of CDK4/6 inhibitors on survival in postmenopausal HR+ HER2-negative metastatic breast cancer

    Expert Review of Anticancer Therapy, 2025

    DOI 10.1080/14737140.2025.2490289 PMID 40200428 3 atıf (OpenAlex) Kaynak: OpenAlex

  20. Comparison of Frontline FOLFIRINOX with Fluorouracil-Based and Gemcitabine-Based Chemotherapies in Metastatic Ampullary Adenocarcinoma: A Multicenter Study by the Turkish Oncology Group (TOG)

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14165868 PMID 40869694 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  21. Comparison of frontline FOLFIRINOX with fluorouracil-based and gemcitabine-basedchemotherapies in metastatic ampullary adenocarcinoma: A multicenter cohort study.

    Journal of Clinical Oncology, 2025

    DOI 10.1200/jco.2025.43.16_suppl.e16264 Açık erişimli tam metinKaynak: OpenAlex

  22. Correlation of PD-L1 and HIF-1 Alpha Expression with KRAS Mutation and Clinicopathological Parameters in Non-Small Cell Lung Cancer

    Current Issues in Molecular Biology, 2025

    DOI 10.3390/cimb47020121 PMID 39996842 3 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  23. Health-related quality of life and psychosocial outcomes in long-term survivors treated with immune checkpoint inhibitors: a nationwide multicenter study

    Frontiers in Immunology, 2025

    DOI 10.3389/fimmu.2025.1693295 PMID 41451229 3 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  24. Real-world evidence of ribociclib-induced hepatotoxicity in patients with breast cancer: a multi-center experience

    BMC Cancer, 2025

    DOI 10.1186/s12885-025-15181-x PMID 41316060 2 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  25. 2079eP The NLA score as a prognostic biomarker in advanced driver-negative NSCLC treated with immunotherapy-based strategies

    Annals of Oncology, 2025

    DOI 10.1016/j.annonc.2025.08.2700 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  26. Comparative efficacy of adjuvant FOLFOX versus FLOT following neoadjuvant FLOT in locally advanced gastric cancer.

    Journal of Clinical Oncology, 2025

    DOI 10.1200/jco.2025.43.16_suppl.e16120 Açık erişimli tam metinKaynak: OpenAlex

  27. 2822P Health-related quality of life and psychosocial outcomes in long-term survivors treated with ICIs: A nationwide multicenter study

    Annals of Oncology, 2025

    DOI 10.1016/j.annonc.2025.08.3434 Açık erişimli tam metinKaynak: OpenAlex

  28. Large Unstained Cells (LUC): A Novel Predictor of CDK4/6 Inhibitor Outcomes in HR+ HER2-Negative Metastatic Breast Cancer

    Journal of Clinical Medicine, 2024

    DOI 10.3390/jcm14010173 PMID 39797256 2 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  29. Prognostic significance of pretreatment clinical and laboratory features in patients with ovarian cancer receiving neoadjuvant chemotherapy

    Oncology in Clinical Practice, 2024

    DOI 10.5603/ocp.100576 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: ORCID

  30. Efficacy and safety of G-CSF prophylaxis in patients with extensive-stage small cell lung cancer receiving Chemoimmunotherapy

    Expert Opinion on Pharmacotherapy, 2024

    DOI 10.1080/14656566.2024.2391007 PMID 39115275 4 atıf (Europe PMC) Kaynak: ORCID

  31. A current comprehensive role of immune-checkpoint inhibitors in resectable non-small cell lung cancer: A narrative review

    Journal of Oncology Pharmacy Practice, 2024

    DOI 10.1177/10781552241260864 PMID 38860323 3 atıf (Europe PMC) Kaynak: ORCID

  32. 1875P Real-world evidence of ribociclib induced liver toxicity in patients with breast cancer: A multi-center experience

    Annals of Oncology, 2024

    DOI 10.1016/j.annonc.2024.08.1969 3 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  33. IMMUNOTHERAPY FOR CERVICAL CANCER

    Turkiye Klinikleri eBooks, 2024

    DOI 10.5336/978-625-395-244-0_p113 Kaynak: OpenAlex

  34. Prognostic and predictive value of tumor infiltrating lymphocytes in combination with systemic inflammatory markers in colon cancer

    Clinics and Research in Hepatology and Gastroenterology, 2023

    DOI 10.1016/j.clinre.2023.102171 PMID 37352926 19 atıf (OpenAlex) Kaynak: OpenAlex

  35. Role of the prognostic nutritional index in the treatment prediction of stage II colon cancer

    Research Square, 2023

    DOI 10.21203/rs.3.rs-2786751/v1 Açık erişimli tam metinKaynak: OpenAlex

  36. 456P Prognostic and predictive value of tumor-infiltrating lymphocytes in combination with systemic inflammatory markers in colon cancer

    Annals of Oncology, 2021

    DOI 10.1016/j.annonc.2021.08.977 2 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex